To the Editor Dr Stupp and colleagues1 reported on the combined use of temozolomide and tumor-treating fields (TTFields) compared with temozolomide alone as adjuvant therapy in patients with newly diagnosed glioblastoma. The study of 315 patients demonstrated improvement in progression-free survival (3.1 months) and overall survival (4.9 months) in the TTFields-treated cohort (210 patients). The question is whether this study, an interim analysis of the total study population of 695 patients, is sufficiently compelling to change current therapies for glioblastoma.
Chamberlain MC. Treatment for Patients With Newly Diagnosed Glioblastoma. JAMA. 2016;315(21):2348. doi:10.1001/jama.2016.1844